---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-015276"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:35:15.483406+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics launches $250M equity offering; prelim cash $331.2M

## Summary
- Preliminary cash, equivalents and short-term investments of $331.2M as of Dec 31, 2022 (unaudited).
- Public offering of 8.33M shares at $30/share; gross proceeds ~$250M (or ~$287.5M if overallotment exercised).
- Underwriters: J.P. Morgan and Piper Sandler; offering expected to close Jan 27, 2023.
- Company also granted underwriters 30-day option for up to 1.25M additional shares.

## SEC filing metadata
- accession: 0001193125-23-015276
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312523015276/0001193125-23-015276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312523015276/d455919d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-015276
- JSON: https://secwatch.observer/filing/0001193125-23-015276.json
- Plain text: https://secwatch.observer/filing/0001193125-23-015276.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported preliminary financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: preliminary results
  source text: Our financial statements for the quarter and year ended December 31, 2022 will not be available until after this offering is completed and consequently will not be available to you prior to investing in this offering. Based upon preliminary estimates and information available to us as of the date of this prospectus supplement, we expect to report that we had approximately $331.2 million of cash, cash equivalents and short-term investments as of December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000119312523015276/0001193125-23-015276-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.